Search Results - "Mahnke, L"

A phase I, open-label, multiple-ascending-dose trial to investigate the safety, tolerability, pharmacokinetics, biological, and clinical activity of M7824, a novel bifunctional fusion protein targeting the PD-L1 and TGF-β pathways, in patients with metastatic or locally advanced solid tumors by Strauss, J, Heery, C, Schlom, J, Madan, R.A, Lamping, E, Marte, J, Cordes, L, Lan, Y, Mahnke, L, Helwig, C, Lo, K.M, Gulley, J

Get full text

Vascular endothelial growth factor and interleukin-6 in peritoneal fluid of women with endometriosis by Mahnke, J L, Dawood, M Y, Huang, J C

“…To determine [1] vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) levels in peritoneal fluid from women with endometriosis and compare them…”
Get more information

45 Drug-drug interactions between ivacaftor and midazolam or rosiglitazone in healthy volunteers by Chen, Y, Huang, J, Ordonez, C.L, Zhang, J, Mahnke, L, Zha, J

Get full text

Effect of Pseudomonas aeruginosa elastase, alkaline protease, and exotoxin A on corneal proteinases and proteins by Twining, SS, Kirschner, SE, Mahnke, LA, Frank, DW

“…To determine the effects of exoproducts from the corneal pathogen Pseudomonas aeruginosa on corneal proteinases and proteins. Whole rabbit corneas were…”
Get full text

Association Between Tumour Lesion Size and Health-Related Quality of Life Outcomes in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab by Kaufman, H, Mahnke, L, von Heydebreck, A, Bharmal, M

“…OBJECTIVES: In patients with metastatic Merkel cell carcinoma (mMCC), a rare and aggressive skin cancer, changes in tumour size during treatment may be…”
Get full text

PCN238 - Association Between Tumour Lesion Size and Health-Related Quality of Life Outcomes in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab by Kaufman, H, Mahnke, L, von Heydebreck, A, Bharmal, M

Get full text

NON-PROGRESSION ON TREATMENT WITH AVELUMAB CONTRIBUTES TO GAINS IN HEALTH UTILITY SCORES IN PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA by Kaufman, H, Hunger, M, Mahnke, L, Schlichting, M, Bharmal, m

“…OBJECTIVES: Patient-reported outcomes are an important component of drug benefit/risk and reimbursement evaluation, but limited data are available from…”
Get full text

NMS-01940153E, an MPS1 inhibitor with anti-tumor activity in relapsed or refractory unresectable Hepatocellular carcinoma by Reig, M., Damian, S., Roberti, D., Maruzzelli, S., Crivori, P., Gianellini, L., De Pietro, M.T., Personeni, N., Sanduzzi-Zamparelli, M., Duca, M., Disconzi, L., Montagnoli, A., Galvani, A., Ardini, E., Isacchi, A., Colajori, E., Davite, C., Mahnke, L., Rimassa, L.

Get full text

Evaluation of real world treatment outcomes in patients with metastatic merkel cell carcinoma (MCC) following second line chemotherapy by Becker, J., Lorenz, E., Haas, G., Helwig, C., Oksen, D., Mahnke, L., Bharmal, M.

Get full text

REAL-WORLD OUTCOMES IN PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA TREATED WITH FIRST-LINE CHEMOTHERAPY IN THE UNITED STATES: RESULTS FROM A RETROSPECTIVE ANALYSIS by Cowey, CL, Mahnke, L, Espirito, J, Helwig, C, Oksen, D, Bharmal, M

“…OBJECTIVES: This retrospective study examined therapeutic outcomes to first-line (1L) chemotherapy in patients with distant metastatic Merkel cell carcinoma…”
Get full text

PSYCHOMETRIC VALIDATION OF THE FACT-M QUESTIONNAIRE IN PATIENTS WITH MERKEL CELL CARCINOMA by Bharmal, M, Fofana, F, Barbosa, C Dias, Mahnke, L, Schlichting, M

“…OBJECTIVES: Assessment of patient-reported outcomes in oncology clinical trials is required to demonstrate treatment benefit from a patient's perspective. No…”
Get full text

Tn5: A Molecular Window on Transposition by Reznikoff, William S., Bhasin, Archna, Davies, Douglas R., Goryshin, Igor Y., Mahnke, Lisa A., Naumann, Todd, Rayment, Ivan, Steiniger-White, Mindy, Twining, Sally S.

“…DNA transposition is an underlying process involved in the remodeling of genomes in all types of organisms. We analyze the multiple steps in cut-and-paste…”
Get full text

Real-World Outcomes of Patients with Metastatic Merkel Cell Carcinoma Treated with Second-Line or Later Chemotherapy in A Community Oncology Setting in The United States by Cowey, CL, Mahnke, L, Espirito, J, Fox, P, Helwig, C, Oksen, D, Bharmal, M

Get full text

PCN206 - Patient Perspectives on Merkel Cell Carcinoma (MCC) and Its Treatment with A Novel Agent (AVELUMAB): Findings From In-Depth Qualitative Patient Interviews by Kaufman, H, Kraemer, M, Dias Barbosa, C, Lambert, J, Mahnke, L, Bharmal, M

Get full text

Patient Perspectives on Merkel Cell Carcinoma (MCC) and Its Treatment with A Novel Agent (AVELUMAB): Findings From In-Depth Qualitative Patient Interviews by Kaufman, H, Kraemer, M, Dias Barbosa, C, Lambert, J, Mahnke, L, Bharmal, M

Get full text

PCN50 - Real-World Outcomes of Patients with Metastatic Merkel Cell Carcinoma Treated with Second-Line or Later Chemotherapy in A Community Oncology Setting in The United States by Cowey, CL, Mahnke, L, Espirito, J, Fox, P, Helwig, C, Oksen, D, Bharmal, M

Get full text

314 - A phase I, open-label, multiple-ascending-dose trial to investigate the safety, tolerability, pharmacokinetics, biological, and clinical activity of M7824, a novel bifunctional fusion protein targeting the PD-L1 and TGF-β pathways, in patients with metastatic or locally advanced solid tumors by Strauss, J., Heery, C., Schlom, J., Madan, R.A., Lamping, E., Marte, J., Cordes, L., Lan, Y., Mahnke, L., Helwig, C., Lo, K.M., Gulley, J.

Get full text

A phase I, open-label, multiple-ascending-dose trial to investigate the safety, tolerability, pharmacokinetics, biological, and clinical activity of M7824, a novel bifunctional fusion protein targeting the PD-L1 and TGF-ß pathways, in patients with metastatic or locally advanced solid tumors by Strauss, J, Heery, C, Schlom, J, Madan, RA, Lamping, E, Marte, J, Cordes, L, Lan, Y, Mahnke, L, Helwig, C, Lo, KM, Gulley, J

“…Background: M7824 is a novel Afunctional fusion protein that simultaneously blocks two major mechanisms of tumor immune evasion. It combines an anti-programmed…”
Get full text

SEROLOGIC SURVEY FOR ANTIBODIES TO BORRELIA BURGDORFERI IN WHITE-TAILED DEER IN GEORGIA by Mahnke, Gail L., Stallknecht, David E., Greene, Craig E., Nettles, Victor F., Marks, Margaret A.

“…A serologic survey for antibodies to Borrelia burgdorferi utilizing an enzyme-linked immunosorbent assay (ELISA) was conducted on white-tailed deer (Odocoileus…”
Get full text

Electrocardiographic changes in HIV-infected, drug experienced patients treated with atazanavir by Mahnke, Lisa, Child, Michael, Satin, Lawrence, Persson, Anna, Bertz, Richard, Lawrence, John

“…After reading the case study of 75 HIV infected patients treated with atazanavir-based therapy reported by Gianotti et al., we express concerns regarding the…”
Get full text